Pallas Capital Advisors LLC Invests $5.20 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Pallas Capital Advisors initiated a $5.20 million position in Thermo Fisher Scientific during the second quarter by purchasing 10,365 shares. Institutional investors and hedge funds collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with Thermo Fisher receiving a “Moderate Buy” consensus rating and an average price target of $619.41, despite HSBC downgrading the stock to “Hold.”
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in adjusted EPS and $11.99 billion in revenue, while revenue increased 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share.

Pallas Capital Advisors LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,365 shares of the medical research company's stock, valued at approximately $5,197,000.

Several other hedge funds have also recently bought and sold shares of TMO. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP grew its holdings in Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. State Street Corp increased its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after buying an additional 229,630 shares during the period. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock valued at $4,728,129,000 after acquiring an additional 26,425 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TMO. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and decreased their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. Finally, KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Trading Up 0.8%

TMO opened at $590.00 on Wednesday. The stock has a market capitalization of $218.15 billion, a price-to-earnings ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a 50-day simple moving average of $533.64 and a 200 day simple moving average of $508.36.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the firm earned $4.28 EPS. The business's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source